Biodexa Pharmaceuticals (NASDAQ:BDRX) Upgraded by Wall Street Zen to Hold Rating

Biodexa Pharmaceuticals (NASDAQ:BDRX) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Friday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Trading Down 0.9%

Shares of Biodexa Pharmaceuticals stock traded down $0.02 on Friday, reaching $2.15. 157,547 shares of the stock were exchanged, compared to its average volume of 469,344. Biodexa Pharmaceuticals has a 1-year low of $2.03 and a 1-year high of $92.00. The business has a fifty day moving average price of $3.69 and a two-hundred day moving average price of $5.84.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.